|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, ABL1
Test Code39033
CPT Codes
88271 (x2), 88275
Preferred Specimen
3 mL bone marrow or 5 mL whole blood collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL bone marrow • 3 mL whole blood
Other Acceptable Specimens
Bone marrow or whole blood collected in: sodium heparin (royal blue-top) tube, or sodium heparin lead-free (tan-top) tube • Bone marrow collected in transport medium
Instructions
Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided with test order.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: See Instructions
Refrigerated: See Instructions
Frozen: See Instructions
Refrigerated: See Instructions
Frozen: See Instructions
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Monday-Sunday Morning Report available: 5 Days
Reference Range
See Laboratory Report
Clinical Significance
High-risk B-ALL; BCR-ABL1-like B-ALL or Ph-like B-ALL with ABL class fusions diagnosis and evaluation for targeted therapy. Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as a BCR-ABL-1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of active kinase signaling. It exhibits adverse clinical features, confers poor prognosis and harbors a diverse range of genetic alterations that active cytokine receptors genes and kinase signaling pathways making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy.